glp 1 noom expands its GLP-1 range with 'microdose' package Hey Sunshines ☀️, This year

It is a GLP-1 agonist like the other medications in this chapter, and also a glucose-dependent insulinotropic polypeptide (GIP) agonist

Its mechanism centers on actin sequestration and the modulation of cell migration, which is why it appears so often in muscle, tendon, and cardiac repair research

No regulatory authority Health Canada, the FDA, the EMA, the TGA, or any equivalent has cleared either component compound, or the blend formulation, as a drug for human or veterinary use

Cost differences are significant

The added GIP activity influences fat cell metabolism, enhances insulin secretion in a glucose-dependent manner, and appears to modulate appetite through additional central nervous system pathways that GLP-1 alone doesnt reach